Evidence map›Paper›PMID 39998662›Full record

ArticleClinical research in cardiology : official journal of the German Cardiac Society2025

Clinical outcomes after complex and high-risk percutaneous coronary intervention according to baseline chronic kidney disease.

Francesca Maria Di Muro, Samantha Sartori, Birgit Vogel, Yihan Feng, Mauro Gitto, Angelo Oliva, Prakash Krishnan, Benjamin Bay, Joseph Sweeny, Pedro Moreno and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Francesca Maria Di MuroIcahn School of Medicine at Mount Sinai, Mount Sinai Fuster Heart Hospital, New York, NY, USA.
Samantha SartoriIcahn School of Medicine at Mount Sinai, Mount Sinai Fuster Heart Hospital, New York, NY, USA.
Birgit VogelIcahn School of Medicine at Mount Sinai, Mount Sinai Fuster Heart Hospital, New York, NY, USA.
Yihan FengIcahn School of Medicine at Mount Sinai, Mount Sinai Fuster Heart Hospital, New York, NY, USA.
Mauro GittoIcahn School of Medicine at Mount Sinai, Mount Sinai Fuster Heart Hospital, New York, NY, USA.
Angelo OlivaIcahn School of Medicine at Mount Sinai, Mount Sinai Fuster Heart Hospital, New York, NY, USA.
Prakash KrishnanIcahn School of Medicine at Mount Sinai, Mount Sinai Fuster Heart Hospital, New York, NY, USA.
Benjamin BayIcahn School of Medicine at Mount Sinai, Mount Sinai Fuster Heart Hospital, New York, NY, USA.
Joseph SweenyIcahn School of Medicine at Mount Sinai, Mount Sinai Fuster Heart Hospital, New York, NY, USA.
Pedro MorenoIcahn School of Medicine at Mount Sinai, Mount Sinai Fuster Heart Hospital, New York, NY, USA.
Parasuram KrishnamoorthyIcahn School of Medicine at Mount Sinai, Mount Sinai Fuster Heart Hospital, New York, NY, USA.
George DangasIcahn School of Medicine at Mount Sinai, Mount Sinai Fuster Heart Hospital, New York, NY, USA.
Annapoorna KiniIcahn School of Medicine at Mount Sinai, Mount Sinai Fuster Heart Hospital, New York, NY, USA.
Samin SharmaIcahn School of Medicine at Mount Sinai, Mount Sinai Fuster Heart Hospital, New York, NY, USA.
Roxana MehranIcahn School of Medicine at Mount Sinai, Mount Sinai Fuster Heart Hospital, New York, NY, USA. roxana.mehran@mountsinai.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic kidney disease (CKD) is associated with unfavorable outcomes in patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI). However, its prognostic role in patients undergoing complex high-risk PCI (CHIP) remains unexplored, prompting our investigation.

methodsConsecutive CHIP patients treated at a tertiary care center from 2012 to 2022 were included in the current analysis. CHIP was identified by the presence of at least one patient and one procedural criterion from a validated score. Patients were stratified by CKD status, with CKD defined as eGFR < 60 ml/min/1.73m

resultsAmong 4855 CHIP patients, 39.6% (n = 1925) had CKD at baseline. CKD patients were older, with more comorbidities, and complex CAD. After multivariable adjustment, CKD was associated with increased 1-year risks of MACE (primarily driven by all-cause mortality and MI rates), and bleeding. In-hospital adjusted hazards for ischemic and bleeding events were similar between the two cohorts, while CA-AKI occurred twice as often in CKD patients compared to non-CKD ones.

conclusionsIn CHIP patients, CKD is a strong predictor of ischemic and bleeding events at one-year follow-up and doubles the risk of post-procedural CA-AKI, underscoring the need for tailored risk assessment and management of this vulnerable population.

Indexed as

Coronary Artery DiseasePercutaneous Coronary InterventionPostoperative ComplicationsRenal Insufficiency, ChronicAgedFemaleFollow-Up StudiesGlomerular Filtration RateHumansIncidenceMaleMiddle AgedPrognosisRetrospective StudiesRisk AssessmentRisk FactorsCHIPCKDComplex high-risk PCIOutcomes

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.